The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- First Biosimilar Application Disclosed: FDA Has Early 2015 Deadline To Resolve Naming, Labeling Issues For New Category Jul. 24, 2014
- Defining “Personalized Medicine” May Be Key First Step To Incentives; FDA Wary Of Constraints But Eager For Resources Jul. 23, 2014
- Tax Inversions: Senate Finance Committee “Must Respond” But No Legislative Path Forward At Present Jul. 23, 2014
See More Research Notes